Popis: |
Oda Jensen,1 Andreas Kiesbye Øvlisen,1,2 Lasse Hjort Jakobsen,1,2 Anne Stidsholt Roug,1,2 René Ernst Nielsen,2,3 Claus Werenberg Marcher,4 Lene Hyldahl Ebbesen,5 Kim Theilgaard-Mönch,6 Peter Møller,7 Claudia Schöllkopf,8 Christian Torp-Pedersen,9,10 Tarec Christoffer El-Galaly,1,2 Marianne Tang Severinsen1,2 1Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark; 2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark; 4Department of Haematology, Odense University Hospital, Odense, Denmark; 5Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; 6Department of Haematology, Rigshospitalet, Copenhagen, Denmark; 7Department of Haematology, Roskilde Sygehus, Roskilde, Denmark; 8Department of Haematology, Herlev Hospital, Herlev, Denmark; 9Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital, Aalborg, Denmark; 10Department of Cardiology, Nordsjællands Hospital, Hillerød, DenmarkCorrespondence: Marianne Tang Severinsen, Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark, Email m.severinsen@rn.dkIntroduction: The diagnosis of a life-threatening disease can lead to depression and anxiety resulting in pharmacological treatment. However, use of psychotropic drugs (antidepressants, anxiolytics, and antipsychotics) in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) is undetermined.Methods: Prescription of psychotropic drugs in Danish AML and MDS patients was compared to a cohort matched on age, sex, and country of origin from the Danish background population using national population-based registries.Results: In total, 2404 AML patients (median age 69 years) and 1307 MDS patients (median age 75 years) were included and each matched to five comparators from the background population. Two-year cumulative incidences showed that AML (20.6%) and MDS (21.2%) patients had a high risk of redemption of a psychotropic drug prescription compared to the background population (7.0% and 7.9%). High age, low educational level, and Charlson Comorbidity Index score ≥ 1 was associated with a higher risk in AML and MDS patients. Furthermore, non-curative treatment intent and performance status in AML patients, and high risk MDS were associated with elevated risk of psychotropic drug prescription.Conclusion: In conclusion, diagnoses of AML and MDS were associated with a higher rate of psychotropic drugs prescription compared to the background population.Keywords: acute myeloid leukaemia, myelodysplastic syndrome, depression, anxiety, psychotropic drugs |